Biologic Agents Preserve the C-2 Pedicle in Patients with Rheumatoid Arthritis: A Comparative Imaging Study Using Three-Dimensional Computed Tomography.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
05 2021
Historique:
received: 22 11 2020
revised: 17 02 2021
accepted: 18 02 2021
pubmed: 2 3 2021
medline: 12 8 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

To investigate whether biologic agents (BAs) reduce a narrow C-2 pedicle screw trajectory, which is often a key stabilizer in surgical treatment, in patients with rheumatoid arthritis (RA). A total of 100 patients with RA treated with and without BAs (BA [+] group [n = 50] and BA [-] group [n = 50]), respectively, were included in the present study. Computed tomography (CT) images of their cervical spine, including C-2, were analyzed. The maximum screw diameter at C-2 that could be inserted without breaching the cortex, measured on 3-dimensional images using a CT-based navigation system, was compared between the groups with and without BA administration. Furthermore, the destruction of the atlantoaxial joint was examined using CT images. The risk factors for a narrow C-2 pedicle were elucidated among the patients treated with BAs. The pedicle in the BA (+) group had a significantly larger C-2 maximum screw diameter than the BA (-) group (6.00 mm vs. 5.13 mm, P < 0.001), with less destruction of the atlantoaxial joint. Among the BA (+) group, a longer period until the initial administration of BAs and RA disease duration were associated with a narrow C-2 pedicle. This study suggests that BAs can maintain the trajectory for C-2 pedicle screws, which acts as a key stabilizer in surgical management for the rheumatoid cervical spine, by halting the destruction of the atlantoaxial joint. Early introduction of BAs can be especially important to prevent the narrowing of the C-2 pedicle.

Identifiants

pubmed: 33647486
pii: S1878-8750(21)00289-8
doi: 10.1016/j.wneu.2021.02.096
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antirheumatic Agents 0
Biological Products 0
Tumor Necrosis Factor Inhibitors 0
tocilizumab I031V2H011

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e42-e50

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Takuya Obo (T)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan. Electronic address: ort199@osaka-med.ac.jp.

Takashi Fujishiro (T)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Masahiro Mizutani (M)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Toma Yano (T)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Sachio Hayama (S)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Yoshiharu Nakaya (Y)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Atsushi Nakano (A)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Masashi Neo (M)

Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH